The University of California, San Francisco is conducting 44 clinical trials focused on melanoma and skin cancer, with 21 currently open to eligible participants. These trials represent a significant push to develop new treatment options for patients with advanced melanoma, a deadly form of skin cancer that has spread beyond the original tumor site and cannot be surgically removed. What Are the Most Promising Melanoma Treatments Being Tested? Researchers at UCSF are exploring several innovative approaches to treating advanced melanoma, many of which combine immunotherapy drugs to boost the body's natural ability to fight cancer. One major trial is testing V940 combined with pembrolizumab, an immunotherapy medication, in people with advanced melanoma. The goal is to determine whether this combination helps patients live longer without their cancer growing or spreading compared to those receiving a placebo with pembrolizumab. Another significant trial is investigating fianlimab combined with cemiplimab, two experimental antibody drugs, against an already-approved combination called Opdualag in patients with melanoma. This head-to-head comparison study, called Harmony, will help researchers understand which combination is most effective and safe. A third trial is examining LNS8801, a new drug being tested alone or combined with pembrolizumab in patients with refractory melanoma, meaning cancer that has not responded to standard treatments. This study will randomly assign 135 patients to three different treatment groups to compare how long the cancer remains stable under each approach. How Do These Clinical Trials Work for Melanoma Patients? - Eligibility Requirements: Most UCSF melanoma trials are open to adults ages 18 and older, though some accept participants as young as 16. Patients typically must have advanced or metastatic melanoma, meaning the cancer has spread to other parts of the body or cannot be removed surgically. - Treatment Administration: Depending on the trial, patients may take oral tablets at home once or twice daily, receive intravenous infusions at the clinic every few weeks, or undergo a combination of both approaches. Treatment typically continues for up to two years unless the cancer stops responding or side effects become unacceptable. - Monitoring and Safety: Participants return to the clinic regularly for safety assessments, blood work to measure drug levels, imaging tests to track tumor response, and evaluation of any side effects. Researchers also check whether the body develops antibodies against the study drugs, which could reduce their effectiveness. - Comparison Groups: Many trials use randomization, similar to flipping a coin, to assign patients to different treatment groups. This helps researchers determine which approach works best by comparing outcomes fairly across groups. Why Are Immunotherapy Combinations the Focus of These Trials? Immunotherapy works by helping the immune system recognize and attack cancer cells more effectively. Standard treatment for advanced melanoma already uses immunotherapy drugs like pembrolizumab and nivolumab, but researchers believe combining multiple immunotherapy drugs or pairing them with new experimental medications could improve outcomes for patients whose cancer has not responded to single-drug approaches. The trials also explore targeted therapies for specific genetic mutations found in melanoma cells. For example, one UCSF trial is testing binimetinib and imatinib for patients with stage III-IV melanoma that carries a KIT mutation, a specific genetic change that these drugs are designed to target. What Should Patients Know About Participating? Melanoma patients interested in clinical trial participation should know that these studies offer access to cutting-edge treatments that are not yet widely available. However, participation requires a significant time commitment for clinic visits, monitoring, and follow-up assessments. Patients should discuss with their oncologist whether a specific trial aligns with their cancer stage, prior treatments, and overall health status. The UCSF trials are being conducted at multiple locations, including San Francisco and other sites, making them accessible to patients across different regions. For those seeking advanced melanoma treatment options beyond standard care, these 21 open trials represent meaningful opportunities to potentially benefit from emerging therapies while contributing to medical knowledge that could help future patients.
